Drug-induced liver injury from elexacaftor/ivacaftor/tezacaftor

J Cyst Fibros. 2022 Mar;21(2):e99-e101. doi: 10.1016/j.jcf.2021.07.001. Epub 2021 Jul 16.

Authors

Sarah Lowry¹, Peter J Mogayzel², Kiyoko Oshima³, Wikrom Karnsakul⁴

Affiliations

¹ Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, USA.
² Eudowood Division of Pediatric Respiratory Sciences, Department of Pediatrics, USA.
³ Department of Pathology, Bloomberg School of Public Health, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
⁴ Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, USA. Electronic address: wkarnsa1@jhmi.edu.

PMID: 34275759
DOI: 10.1016/j.jcf.2021.07.001

No abstract available

Keywords: CFTR modulator; Cystic fibrosis; Drug-induced liver injury.

Publication types

Case Reports

MeSH terms

Aminophenols / adverse effects
Benzodioxoles / adverse effects
Chemical and Drug Induced Liver Injury* / diagnosis
Chemical and Drug Induced Liver Injury* / etiology
Chloride Channel Agonists / adverse effects
Cystic Fibrosis Transmembrane Conductance Regulator / genetics
Cystic Fibrosis* / drug therapy
Cystic Fibrosis* / genetics
Drug Combinations
Humans
Indoles
Pyrazoles
Pyridines
Pyrrolidines
Quinolones

Substances

Aminophenols
Benzodioxoles
Chloride Channel Agonists
Drug Combinations
Indoles
Pyrazoles
Pyridines
Pyrrolidines
Quinolones
tezacaftor
Cystic Fibrosis Transmembrane Conductance Regulator
ivacaftor
elexacaftor